바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

2오늘 방문

554누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

CGTSHOTFDACuratedFDABiologicKitevedotin plus bendamustine a…Approved

axicabtagene ciloleucel (Yescarta, axi-cel)

LBCL, FL · CD19

#CD19#CGT#Approved#FDA승인#바이오모아추천+5

효능 ORR 92%임상시험 66상태 APPROVED

ADCBBiologicShanghai Junshi Bioscience Co.,…Phase 2

XELOX (XELOX)

Metastatic HER2 Positive Gastroesophageal Junction Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+3

효능 ORR 47%임상시험 64상태 RECRUITING

ADCCBiologicRemeGen Co., Ltd.Phase 3

Capecitabine tablets (Capecitabine tablets)

Breast Cancer · Recurrent or Metastatic Nasopharyngeal C

#RecurrentorMetastaticNasopharyng#ADC#Phase3#인기#항체약물접합체+3

효능 ORR 35.4%임상시험 62상태 ACTIVE

CGTSHOTFDACuratedFDABiologicNovartisApproved

tisagenlecleucel (Kymriah, tisa-cel)

ALL, DLBCL, FL · CD19

#CD19#CGT#Approved#FDA승인#바이오모아추천+5

효능 ORR 82.3%임상시험 48상태 APPROVED

ADCBBiologicADC TherapeuticsthatPhase 2

Anti-CD19 Antibody-Drug Conjugate (Loncastuximab Tesirine, Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate))

Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL) · CD19

#CD19#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4

효능 ORR 94.1%임상시험 48상태 RECRUITING

ADCSFDAFDABiologicFundación Pública Andaluza para…Deruxtecan-Dlnk Quantificat…Phase 3

Datopotamab deruxtecan (Datopotamab deruxtecan)

Breast Cancer; Metastatic Breast Cancer · Lung Cancer

#LungCancer#ADC#Phase3#FDA승인#항체약물접합체+5

효능 ORR 79%임상시험 44상태 RECRUITING

CGTCBiologicstaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR T cells (4SCAR T cells)

Autoimmune Diseases · Autoimmune Diseases

#AutoimmuneDiseases#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 14상태 RECRUITING

ADCAFDAFDABiologicstaleAbbViePhase 3

Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Advanced Solid Tumors Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase3#FDA승인#항체약물접합체+3

효능 ORR 33.3%임상시험 12상태 RECRUITING

ADCCFDAFDABiologicstaleAstellasPhase 3

enfortumab vedotin (Padcev, Enfortumab Vedotin-Ejfv)

Advanced or Metastatic Solid Malignancies · Advanced or Metastatic Solid Malignancie

#AdvancedorMetastaticSolidMaligna#ADC#Phase3#FDA승인#항체약물접합체+2

임상시험 1상태 ACTIVE

AntibodyHotJanssenApproved

Infliximab (Infliximab)

Cytokine Release Syndrome; Recurrent Multiple Myeloma · Crohn Disease

#CrohnDisease#Antibody#Approved#인기#항체+5

효능 ORR 54.5%임상시험 283상태 ACTIVE

AntibodyAHOTFDACuratedFDABiologicSanofiApproved

dupilumab (Dupixent)

Atopic dermatitis, asthma, CRSwNP, EoE · IL-4Rα

#IL-4R#Antibody#Approved#FDA승인#바이오모아추천+5

효능 ORR 0.45%임상시험 216상태 APPROVED

AntibodyCHotRocheDM1) and trastuzumab deruxt…Phase 3

Pertuzumab (Pertuzumab)

Colorectal Cancer · HER2

#HER2#Antibody#Phase3#인기#항체+5

효능 ORR 91.8%임상시험 204상태 DISCONTINUED

ADCSHotBiologicJanssen Research & Development,…Approved

5-Fluorouracil (5-Fluorouracil)

Colorectal Neoplasms · Endometrial Cancer

#EndometrialCancer#ADC#Approved#인기#항체약물접합체+3

효능 ORR 72.7%임상시험 177상태 RECRUITING

CGTBHotBiologicGlaxoSmithKlinePhase 1

19 (T2, 19, 19(T2)28z1xx TRAC T cell)

B-Cell Lymphoma; Large B-cell Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#CGT#Phase1#인기#세포유전치료+5

효능 ORR 100%임상시험 177상태 RECRUITING

ADCSFDAFDAHotBiologicSeagenvedotin and the anti-HER2 t…Approved

brentuximab vedotin (Adcetris)

Hodgkin Lymphoma · Hodgkin Disease

#HodgkinDisease#ADC#Approved#FDA승인#인기+5

효능 ORR 100%임상시험 167상태 ACTIVE

AntibodyAHotEli Lilly-linkersPhase 2

EGFR inhibitor (Cetuximab, Cetuximab (EGFR inhibitor))

Advanced Solid Tumor; NSCLC · EGFR

#EGFR#Antibody#Phase2#인기#항체+5

효능 ORR 70.6%임상시험 166상태 ACTIVE

AntibodyBHotMerckVedotin ± Pe…Phase 3

Pembrolizumab (Immunotherapy, Immunotherapy (Pembrolizumab))

Melanoma (Skin Cancer); Melanoma Stage IIIB-IV · Locally Advanced Esophageal Squamous Cel

#LocallyAdvancedEsophagealSquamou#Antibody#Phase3#인기#항체+5

효능 ORR 41.6%임상시험 155상태 RECRUITING

AntibodySHOTFDACuratedFDABiologicNovartisApproved

secukinumab (Cosentyx)

Psoriasis, psoriatic arthritis, ankylosing spondylitis · IL-17A

#IL-17A#Antibody#Approved#FDA승인#바이오모아추천+5

효능 ORR 78.1%임상시험 153상태 APPROVED

AntibodyBHotMerckvedotin plus pembrolizumab …Phase 2

PD-1 Blocking Antibody (Pembrolizumab, Pembrolizumab (PD-1 Blocking Antibody))

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · PD-1

#PD-1#Antibody#Phase2#인기#항체+5

효능 ORR 75%임상시험 151상태 ACTIVE

AntibodyBHotJanssenPhase 2

Subcutaneously (Daratumumab, Daratumumab (Subcutaneously))

Primary Plasma Cell Leukemia · Primary Plasma Cell Leukemia

#PrimaryPlasmaCellLeukemia#Antibody#Phase2#인기#항체+3

효능 ORR 91.8%임상시험 147상태 RECRUITING

AntibodyAHotRochePhase 2

combination (Trastuzumab plus Pertuzumab, Trastuzumab plus Pertuzumab (combination))

Cancer; Tumors · Cancer

#Cancer#Antibody#Phase2#인기#항체+5

효능 ORR 88.6%임상시험 144상태 RECRUITING

ADCBHotBiologicAstraZenecavedotin plus PD-1 blockade …Phase 3

GEM (Gemcitabine, Gemcitabine (GEM))

Extranodal NK/T-cell Lymphoma · Nasopharyngeal Carcinoma (NPC)

#NasopharyngealCarcinomaNPC#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 50%임상시험 133상태 RECRUITING

ADCAHotBiologicMerck Sharp & Dohme LLCderuxtecan (T-DXd) plus 5-f…Phase 2

5-FU (5-fluorouracil, 5-fluorouracil (5-FU))

Gastroesophageal Junction; Gastroesophageal Adenocarcinoma · Colorectal Cancer

#ColorectalCancer#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 72.7%임상시험 126상태 RECRUITING

AntibodySHOTFDACuratedFDABiologicRocheApproved

ranibizumab (Lucentis, Byooviz, Cimerli)

Wet AMD, DME, RVO, myopic CNV · VEGF-A

#VEGF-A#Antibody#Approved#FDA승인#바이오모아추천+5

효능 ORR 68%임상시험 124상태 APPROVED

ADCBHotBiologicSeagenVedotin: A Retrospective Co…Phase 3

Bv (Brentuximab Vedotin, Brentuximab Vedotin (Bv))

Cutaneous T Cell Lymphoma (CTCL); Brentuximab Vedotin · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 100%임상시험 123상태 ACTIVE

2 / 167 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 2 / 554

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

axicabtagene ciloleucel (Yescarta, axi-cel)

XELOX (XELOX)

Capecitabine tablets (Capecitabine tablets)

tisagenlecleucel (Kymriah, tisa-cel)

Anti-CD19 Antibody-Drug Conjugate (Loncastuximab Tesirine, Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate))

Datopotamab deruxtecan (Datopotamab deruxtecan)

4SCAR T cells (4SCAR T cells)

Telisotuzumab Vedotin (Telisotuzumab Vedotin)

enfortumab vedotin (Padcev, Enfortumab Vedotin-Ejfv)

Infliximab (Infliximab)

dupilumab (Dupixent)

Pertuzumab (Pertuzumab)

5-Fluorouracil (5-Fluorouracil)

19 (T2, 19, 19(T2)28z1xx TRAC T cell)

brentuximab vedotin (Adcetris)

EGFR inhibitor (Cetuximab, Cetuximab (EGFR inhibitor))

Pembrolizumab (Immunotherapy, Immunotherapy (Pembrolizumab))

secukinumab (Cosentyx)

PD-1 Blocking Antibody (Pembrolizumab, Pembrolizumab (PD-1 Blocking Antibody))

Subcutaneously (Daratumumab, Daratumumab (Subcutaneously))

combination (Trastuzumab plus Pertuzumab, Trastuzumab plus Pertuzumab (combination))

GEM (Gemcitabine, Gemcitabine (GEM))

5-FU (5-fluorouracil, 5-fluorouracil (5-FU))

ranibizumab (Lucentis, Byooviz, Cimerli)

Bv (Brentuximab Vedotin, Brentuximab Vedotin (Bv))

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

axicabtagene ciloleucel (Yescarta, axi-cel)

XELOX (XELOX)

Capecitabine tablets (Capecitabine tablets)

tisagenlecleucel (Kymriah, tisa-cel)

Anti-CD19 Antibody-Drug Conjugate (Loncastuximab Tesirine, Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate))

Datopotamab deruxtecan (Datopotamab deruxtecan)

4SCAR T cells (4SCAR T cells)

Telisotuzumab Vedotin (Telisotuzumab Vedotin)

enfortumab vedotin (Padcev, Enfortumab Vedotin-Ejfv)

Infliximab (Infliximab)

dupilumab (Dupixent)

Pertuzumab (Pertuzumab)

5-Fluorouracil (5-Fluorouracil)

19 (T2, 19, 19(T2)28z1xx TRAC T cell)

brentuximab vedotin (Adcetris)

EGFR inhibitor (Cetuximab, Cetuximab (EGFR inhibitor))

Pembrolizumab (Immunotherapy, Immunotherapy (Pembrolizumab))

secukinumab (Cosentyx)

PD-1 Blocking Antibody (Pembrolizumab, Pembrolizumab (PD-1 Blocking Antibody))

Subcutaneously (Daratumumab, Daratumumab (Subcutaneously))

combination (Trastuzumab plus Pertuzumab, Trastuzumab plus Pertuzumab (combination))

GEM (Gemcitabine, Gemcitabine (GEM))

5-FU (5-fluorouracil, 5-fluorouracil (5-FU))

ranibizumab (Lucentis, Byooviz, Cimerli)

Bv (Brentuximab Vedotin, Brentuximab Vedotin (Bv))

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

axicabtagene ciloleucel (Yescarta, axi-cel)

XELOX (XELOX)

Capecitabine tablets (Capecitabine tablets)

tisagenlecleucel (Kymriah, tisa-cel)

Anti-CD19 Antibody-Drug Conjugate (Loncastuximab Tesirine, Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate))

Datopotamab deruxtecan (Datopotamab deruxtecan)

4SCAR T cells (4SCAR T cells)

Telisotuzumab Vedotin (Telisotuzumab Vedotin)

enfortumab vedotin (Padcev, Enfortumab Vedotin-Ejfv)

Infliximab (Infliximab)

dupilumab (Dupixent)

Pertuzumab (Pertuzumab)

5-Fluorouracil (5-Fluorouracil)

19 (T2, 19, 19(T2)28z1xx TRAC T cell)

brentuximab vedotin (Adcetris)

EGFR inhibitor (Cetuximab, Cetuximab (EGFR inhibitor))